Authors
Latest:
Dr. Starr on the Characterization of POLE/POLD1 Mutations in Colorectal AdenocarcinomaJason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.
Latest:
Dr Weiss on the Ongoing Investigation of Tebentafusp With or Without Pembrolizumab in Non-Uveal MelanomaSarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.
Latest:
Strategic Approaches to Biomarker Testing in NSCLC: Optimal TimingExperts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.
Latest:
Dr. Yilmaz on the Benefit of Quizartinib Triplet in AMLMusa Yilmaz, MD, discusses composite complete remission and bone marrow transplant rates observed in a phase 1/2 trial in patients with FLT3-ITD–mutated acute myeloid leukemia.
Latest:
Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIsEmily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.
Latest:
Dr Smith on Next Steps With the KELIM Score and HIPEC in Epithelial Ovarian CancerGabriella Smith, MD, discusses the predictive value of KELIM for survival outcomes with HIPEC at the time of surgery in epithelial ovarian cancer.
Latest:
Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap SyndromesDouglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.
Latest:
Dr. Ghali on Nectin-4 and TROP-2 Expression in Urothelial, Variant Histology Bladder CancerFady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.
Latest:
BCMA-Targeting Therapies for RRMM: Future PerspectivesConsiderations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.
Latest:
Dr. Hwu on the Uptake of Cellular Therapy in OncologyPatrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.
Latest:
Dr Reichert on Key Research Questions in Prostate CancerZachery Roger Reichert, MD, PhD, discusses key research questions to explore in early-stage prostate cancer.
Latest:
Dr Koo on Challenges With PSMA PET in Prostate CancerPhillip J. Koo, MD, discusses the utility of next-generation imaging in prostate cancer, highlighting the use of PSMA PET in this patient population.
Latest:
Current Standard of Care for Locally Advanced or Metastatic Cutaneous Squamous Cell CarcinomaNikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses current therapeutic options for patients with locally advanced cutaneous squamous cell carcinoma.
Latest:
Dr Christenson on Copanlisib Plus Nivolumab in Pretreated PIK3Ca+ MSS mCRCEric S. Christenson, MD, discusses efficacy data for copanlisib plus nivolumab in patients with pretreated, MSS metastatic colorectal cancer.
Latest:
Small Cell Lung Cancer: What is the Role of IO Therapy in the Frontline Setting?A brief review of the role that immunotherapy agents play in the frontline management of patients with small cell lung cancer.
Latest:
Dr Di Federico on an Analysis of TTF-1 Expression in Lung AdenocarcinomaAlessandro Di Federico, MD, discusses findings from a study investigating the correlation between TTF-1 expression and outcomes with immunotherapy-based treatments in patients with lung adenocarcinoma.
Latest:
Dr. Seetharamu on Individualized Care in SCLCNagashree Seetharamu, MD, MBBS, discusses interpreting the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology and deciding when to initiate hospice care in patients with small cell lung cancer.
Latest:
Dr Badar on Outcomes With Imetelstat in Lower-Risk MDSTalha Badar, MBBS, MD, discusses key efficacy data with imetelstat from the phase 2/3 IMerge trial of patients with lower-risk myelodysplastic syndrome.
Latest:
Dr Spiegel on the Challenges Associated With CAR T-Cell Therapy in Solid TumorsJay Spiegel, MD, discusses some of the challenges of using CAR T-cell therapy in patients with solid tumors.
Latest:
Dr. Davis on the Influence of Racial Constructs and Genetic Ancestry in TNBCMelissa B. Davis, PhD, discusses the influence of racial constructs and genetic ancestry in triple negative breast cancer.
Latest:
Dr Saltos on Pembrolizumab Plus Vorinostat in mNSCLCAndreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.
Latest:
Dr Arianna Gianakos: Innovation and Trailblazing Paths in OrthobiologicsArianna Gianakos, DO, discusses the innovation in orthobiologics and trailblazing paths in equity and advocacy.
Latest:
Building Upon ScaffoldsCancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.
Latest:
Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPCDrs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.
Latest:
Dr. Buske on the Results of the iNNOVATE Trial in Waldenström MacroglobulinemiaChristian Buske, MD, discusses the results of the iNNOVATE trial in Waldenström macroglobulinemia.
Latest:
Dr. Jeyarajah on Aggressive Treatment while Preserving Quality of Life in CRCRohan Jeyarajah, MD, discusses aggressive treatment while preserving quality of life in patients with colorectal cancer.
Latest:
Data Quality Issues Plague the US Health Care SystemOleg Bess, MD, explains why data quality is essential to improving the United States health care system.
